Monday, January 06, 2020 9:32:53 PM
Are Options Traders Betting on a Big Move in Savara (SVRA) Stock?
Investors in Savara Inc. SVRA need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2020 $5.00 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Savara shares, but what is the fundamental picture for the company? Currently, Savara is a Zacks Rank #3 (Hold) in the Medical - Drugs industry that ranks in the Top 23% of our Zacks Industry Rank. Over the last 30 days, one analyst has increased the earnings estimate for the current quarter, while none have dropped their estimates. The net effect has narrowed our Zacks Consensus Estimate for the current quarter from a loss of 52 cents per share to a loss of 49 cents in that period.
Given the way analysts feel about Savara right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
https://finance.yahoo.com/news/options-traders-betting-big-move-143002217.html
GO SVRA
"PEACE"
Recent SVRA News
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 10/24/2024 06:02:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/22/2024 08:10:52 PM
- Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV • Business Wire • 10/22/2024 12:05:00 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 10/18/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/01/2024 08:37:38 PM
- Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting • Business Wire • 10/01/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2024 08:35:29 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2024 08:33:27 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 09/27/2024 08:05:00 PM
- Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 09/27/2024 12:05:00 PM
- Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately • Business Wire • 09/24/2024 12:05:00 PM
- Savara to Host Analyst and Investor Webinar on September 30, 2024 • Business Wire • 09/23/2024 12:05:00 PM
- Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 • Business Wire • 09/08/2024 10:45:00 AM
- Savara Announces New Employment Inducement Grant • Business Wire • 09/06/2024 08:05:00 PM
- Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 09/03/2024 08:05:00 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 08/16/2024 08:05:00 PM
- Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 • Business Wire • 08/15/2024 12:05:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/15/2024 12:45:41 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:05:21 PM
- Savara Reports Second Quarter 2024 Financial Results and Provides Business Update • Business Wire • 08/12/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/26/2024 08:09:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/22/2024 08:16:53 PM
- Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock • Business Wire • 06/28/2024 12:50:00 PM
- Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 06/26/2024 10:30:00 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM